8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 22, 2013

GENSPERA, INC.

(Exact name of registrant as specified in Charter)

Delaware	0001421204	20-0438951
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(IRS Employee Identification No.)

2511 N Loop 1604 W, Suite 204

San Antonio, TX 78258

(Address of Principal Executive Offices)

210-479-8112

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On January 22, 2013, a representative of GenSpera, Inc. (the “Company”) presented at the San Antonio Emerging Venture Pipeline Quarterly Luncheon in San Antonio, Texas. Included in the presentation was updated information with regard to the Phase Ib portion of the Company’s ongoing clinical trials. Filed herewith as Exhibit 99.01 are the slides that were presented at the luncheon.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in the exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 22, 2013

GenSpera, Inc.
By:	/s/ Craig Dionne
	Craig Dionne Chief Executive Officer

INDEX OF EXHIBITS

			Incorporated by Reference
Exhibit No.	Description	Filed Herewith	Form	Exhibit No.	File No.	Filing Date
99.01	Slides presented at luncheon	*

EX-99.01

Precise targeting of a potent, unique prodrug directly to tumors OTCBB: GNSZ JANUARY 2013

GENSPERA DEFINED Highly differentiated , novel therapeutic agent with a unique mechanism of action GNSZ | JANUARY 2013 PAGE 2 • Thapsigargin has potential for “complete kill” – active against both slowly and rapidly dividing cells and cancer stem cells • IP acquired from Johns Hopkins University – no milestones or royalties due • Lead drug candidate, G - 202, currently in Phase II clinical trials in prostate cancer and hepatocellular carcinoma • Interim Phase II data expected in 2 indications in Q3 2013

"MOLECULAR GRENADES" GNSZ | JANUARY 2013 PAGE 3 Active drug (12ADT) with a targeting/masking agent attached (i.e., the prodrug) is inactive in blood stream – like a grenade with pin intact… …until it finds an enzyme which is found only at “target site ” – contact with enzyme “pulls the pin” off the targeting/masking agent The active drug, no longer soluble, “precipitates” directly into nearby cells and destroys them Normal Normal Target Cell

G - 202 PHASE I RESULTS GNSZ | JANUARY 2013 PAGE 4 • Recommended dosing regimen: IV infusion, 40 mg/m 2 on Day 1, 66.8 mg/m 2 on Days 2 and 3 of 28 - day schedule with hydration and standard pre - meds • Side Effect Profile: Easily managed minimal side effects (fatigue, nausea on Day 1, rash). No apparent effect on liver, cardiovascular system or bone marrow.

G - 202 PHASE IB HCC PATIENTS GNSZ | JANUARY 2013 PAGE 5 Time to disease progression following sorafenib therapy in typical HCC patient population is ~ 8 weeks. Patient Weeks on Study Status A 34 Stable Disease Remains on study B 20 Disease Progression Off study C 23 Stable Disease Remains on study D 8 Disease Progression Off study E 7 Disease Progression Off study

G - 202 PHASE II TRIALS GNSZ | JANUARY 2013 PAGE 6 • Hepatocellular Carcinoma • Population: Patients with progressive advanced hepatocellular cancer following sorafenib therapy • Number of Patients and Sites: 29 patients at 10 sites in Texas (relationship with CTNeT) • Prostate Cancer • Population: Patients with chemotherapy - naïve metastatic castrate - resistant prostate cancer • Number of Patients and Sites: 34 patients at 5 sites in the US and UK

STRATEGY & VALUE CREATION GNSZ | JANUARY 2013 PAGE 7 • Raised ~$ 18M since Nov 2007, majority from repeat investors • Trading symbol: OTCBB:GNSZ Financing History • ~22M common shares issued and outstanding • ~13M currently outstanding options and warrants • Management, inventors, and boards hold approximately 30% of issued shares Business Strategy and Value Creation • Operate with minimal infrastructure requirement • Develop drugs through Phase II clinical trials, then out - license, partner or sale in ~1 - 2 years • Individual drugs can be worth up to $1B • 2009 – J&J/Cougar and Astellas / Medivation • 2011 – Amgen/ Biovex Capital Structure

CORE DISTINCTIONS GNSZ | JANUARY 2013 PAGE 8 Highly differentiated , novel therapeutic agent with a unique mechanism of action • New approach to cancer therapy – not just different but intended to be better • Interim Phase II data expected in 2 indications in Q3 2013 • Out - license, partner or sale subsequent to Phase II • Focus is on rapidly achieving valuation milestones with minimal cost

CONTACT GNSZ | JANUARY 2013 PAGE 9 Craig A. Dionne, PhD President & CEO cdionne@genspera.com GenSpera, Inc. 2511 N Loop 1604 W, Suite 204 San Antonio, TX 78258 www.genspera.com Phone: (210) 479 - 8112 Fax: (210) 479 - 8113